ESUS Fails But Hurt Minimal for Bayer/Janssen's Xarelto
Executive Summary
Bayer and Janssen's bid for NOAC dominance through diversification has hit a buffer with the failure of a Phase III trial in stroke, but the indication is small and not expected to hit sales that much.